Description

This issue of Vital Signs, released on February 8, 2010, provides a strategic overview of challenges and opportunities in next-generation sequencing bioinformatics. Additionally, a company spotlight is provided for CLC bio, a company focused on bioinformatics needs in genomics research, drug discovery, diagnostics, and next-generation sequencing. Reimbursement and regulatory news from the FDA is also provided for the week of January 20, 2010.